• 4D Molecular Therapeutics Inc FDMT.OQ FDMT.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

• The Emeryville California-based company is expected to report a 1,266.3% increase in revenue to $382.57 thousand from $28 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for 4D Molecular Therapeutics Inc is for a loss of 86 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The mean earnings estimate of analysts had risen by about 2.4% in the last three months. ​

• Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $35.00​, above​ its last closing price of $3.76. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated May 5 at 11:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)